Aspen Neuroscience: New Chief Technology Officer
Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson's disease (PD), has welcomed Kim Raineri as Chief Technology Officer and as a member of the company's executive team.
Raineri brings over 25 years of global experience in the cell and gene therapy, biologics and medical device spaces, with a distinguished record of innovation and implementation of Good Manufacturing Practices (GMP). Aspen Neuroscience has been building out its technical operations and team, and Kim will be responsible for developing the strategy for and execution of the company's in-house manufacture of its autologous cell therapy portfolio.
San Diego-based Aspen is entering a ‘historic new stage of growth’ as the first company in the world to reach its current stage of development, where it is manufacturing autologous PD patient iPSCs for use in upcoming clinical trials.
Prior to joining Aspen Neuroscience, Raineri served as chief manufacturing and technology officer and a member of the executive team at AVROBIO, a Boston-based leader in the gene therapy space.
Before AVROBIO, he was vice president of operations for Nikon CeLL innovation Co., Ltd, a Japanese contract development and manufacturing organization. During his tenure, he established the company as the preferred provider of custom process development and manufacturing services for cell and gene therapy products in the Japanese market.
Previously, Raineri also held management positions at Lonza as the business director for cell therapy contract manufacturing operations in Singapore for five years, and as director of operations at Lonza's Maryland facilities. Kim was also previously the senior manager of the Tissue Processing Lab at CryoLife Inc.
Kim earned his Bachelor of Science from the University of Miami and Master's in Business Administration from Kennesaw State University. He is also a frequent presenter and panel member at cell and gene therapy industry meetings and was a mentor for Early Stage Professionals through the International Society for Cell and Gene Therapy.
